Iradimed (IRMD) Stock
Medical technology firm specializing in patient temperature management systems. Here's the price, business snapshot, and what's worth knowing about Iradimed in August 2026.
IRADIMED Corp (IRMD) is a small-cap medical‑technology company that develops patient temperature‑management systems and MRI‑compatible warming and cooling devices, alongside related consumables. Investors should note the business mixes capital equipment sales with recurring revenue from disposables, so growth depends on both device placements and ongoing consumable uptake. Key drivers include hospital purchasing cycles, clinical adoption, regulatory approvals and reimbursement environments. The company’s roughly $960M market capitalisation reflects market expectations but also exposes it to volatility common in specialised med‑tech names. Risks include competitive pressure from larger device manufacturers, dependence on a limited product range, and the timing of regulatory or procurement events. This summary is for educational purposes only and not personal financial advice; suitability depends on your circumstances and risk tolerance. Values can rise and fall, and past performance is not a guide to future results.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying IRADIMED stock, anticipating it could rise to $99 in value.
Financial Health
IRADIMED CORP shows strong profits and cash flow, indicating solid financial performance and stability.
Dividend
IRADIMED CORP's dividend yield of 0.77% is low, which may not appeal to dividend-seeking investors. If you invested $1000 you would be paid $7.70 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Patient temperature tech
Focuses on warming and cooling systems and MRI‑compatible devices; recurring consumables can support revenue, though adoption and reimbursement affect outcomes.
Hospital adoption trends
Sales depend on hospital purchasing cycles, clinical guidelines and training; growth can be uneven as hospitals prioritise budgets.
Regulatory & competitive
Subject to FDA and international approvals and competition from larger med‑tech firms; regulatory setbacks or competitive wins can materially impact performance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
